<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279942</url>
  </required_header>
  <id_info>
    <org_study_id>2155-05</org_study_id>
    <nct_id>NCT00279942</nct_id>
  </id_info>
  <brief_title>Effect of Revival Soy on Fibromyalgia Pain</brief_title>
  <official_title>Effect of Revival Soy on Fibromyalgia Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Physicians Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is characterized by widespread pain that can lead to significant patient
      dysfunction and economic burden to society. The management of patients with fibromyalgia is
      difficult and no single treatment modality has been successful. We propose to study the
      effect of dietary soy supplement on quality of life associated with fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia syndrome is a chronic, generalized pain syndrome that affects the
      musculoskeletal system (1). This syndrome is typically diagnosed in patients who experience
      generalized musculoskeletal pain and have excessive tenderness in at least 11 of 18 specific
      points (2). Although the primary cause of fibromyalgia syndrome is unclear, a growing body of
      evidence indicates that the widespread pain associated with this syndrome is due to
      abnormalities in the central nervous system. Therefore, drug therapy for fibromyalgia
      syndrome is most often aimed at the central nervous system and includes tricyclic
      antidepressants, selective serotonin reuptake inhibitors, dual serotonin and norepinephrine
      reuptake inhibitors, analgesics, and anticonvulsants (1).

      In addition to medical therapies, complementary and alternative medicine therapies have been
      used to treat fibromyalgia syndrome symptoms (3). Soy is a widely used dietary supplement
      that has not been previously tested for treating fibromyalgia syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To gather preliminary data on whether dietary soy supplement can improve quality of life in patients with fibromyalgia as measured by the Fibromyalgia Impact Questionnaire (FIQ) and the Center for Epidemiologic Studies Depression Scale (CES-D).</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the feasibility of recruiting 50 patients with fibromyalgia into a study of using a dietary supplement.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A shake that contained 20 g of milk-based protein (casein) and no isoflavone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy</intervention_name>
    <description>Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.</description>
    <arm_group_label>Soy</arm_group_label>
    <other_name>Isoflavone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men age 18 - 76

          -  Able to understand and sign a consent form

          -  Able to participate fully in all aspects of the study

          -  Currently participating in Mayo Clinic's Fibromyalgia Treatment Program

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Allergy to soy or other study product ingredients

          -  Diagnosis of bipolar disorder, schizophrenia or dementia

          -  Diagnosis of diabetes mellitus or inflammatory bowel disease

          -  Presently on soy product or use of soy within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietlind L. Wahner-Roedler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.revivalsoy.com/</url>
    <description>Revival Soy</description>
  </link>
  <reference>
    <citation>Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004 Nov 17;292(19):2388-95. Review.</citation>
    <PMID>15547167</PMID>
  </reference>
  <reference>
    <citation>Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160-72.</citation>
    <PMID>2306288</PMID>
  </reference>
  <reference>
    <citation>Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003 Aug;17(4):667-83. Review.</citation>
    <PMID>12849718</PMID>
  </reference>
  <results_reference>
    <citation>Wahner-Roedler DL, Thompson JM, Luedtke CA, King SM, Cha SS, Elkin PL, Bruce BK, Townsend CO, Bergeson JR, Eickhoff AL, Loehrer LL, Sood A, Bauer BA. Dietary soy supplement on fibromyalgia symptoms: a randomized, double-blind, placebo-controlled, early phase trial. Evid Based Complement Alternat Med. 2011;2011:350697. doi: 10.1093/ecam/nen069. Epub 2011 Jun 23.</citation>
    <PMID>18990724</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2006</study_first_submitted>
  <study_first_submitted_qc>January 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2006</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Dietlind Wahner-Roedler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Rheumatologic Diseases</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

